SEC Form 4 · accession 0001127602-17-031259
PDS Biotechnology Corp · PDSB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Saik
Officer — Chief Financial Officer
Period of report
Nov 1, 2017
Accepted (ET)
Nov 3, 2017 · 6:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001472091
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right To Purchase)F1 | $10.73 | Nov 1, 2017 | A | 200,000 | A | — | Nov 1, 2027 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1This option, representing a right to purchase a total of 200,000 shares of Common Stock, will become exercisable on October 31, 2018, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.